相关实验视频
Updated: Jun 10, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.6K
多糖体形式甜玉米介导的低血糖效应在体外和非向的代谢学研究2型糖尿病
Jingyang Wang1, Xin Wang1, Weiye Xiu1
1Key Laboratory of Cereal Food and Cereal Resources in Heilongjiang Province, School of Food Engineering, Harbin University of Commerce, Harbin 150028, China.
International journal of biological macromolecules
|October 10, 2024
概括
甜玉米的多糖化物 (SeSCP) 通过调节酶和葡萄糖运输,有效降低2型糖尿病 (T2D) 的血糖. 此外,SeSCP还比甲胺更能改善T2D代谢.
科学领域:
- 生物化学 生物化学
- 代谢学 代谢学 代谢学
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2D) 的特点是代谢障碍和高血糖.
- 甜玉米的多糖化物 (SeSCP) 显示出低血糖潜力,但其在T2D中的代谢作用需要阐明.
研究的目的:
- 在T2D的小鼠模型中研究SeSCP的低血糖和代谢影响.
- 为了比较SeSCP与甲福林和甜玉米多糖化物 (SCP) 的疗效.
主要方法:
- 在体外酶抑制测定α-氨酶和α-葡萄糖酶.
- 在体内研究中,使用高脂肪饮食和链毒素诱导的T2D小鼠模型.
- 使用液体染色学-质谱学 (LC-MS) 的便代谢物分析.
主要成果:
- SeSCP证明了竞争性的α-氨酶和α-葡萄糖酶的可逆抑制.
- SeSCP调节葡萄糖运输,在体内降低血糖水平.
- SeSCP显著改变了便代谢物,影响了诸如β-氨酸,粉/糖和脂质代谢等途径.
- 在代谢干预中,SeSCP的表现优于甲胺和SCP.
结论:
- SeSCP具有显著的低血糖疗效,并改善T2D相关的代谢障碍.
- SeSCP为管理T2D及其并发症提供了一个有前途的治疗策略.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
163
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
163
Hypoglycemia and Glucagon
164
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
164
Oral Hypoglycemic Agents: Biguanides and Glitazones
178
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
178
Carbohydrate Metabolism
10.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.8K
Oral Hypoglycemic Agents: Sulfonylureas
194
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
194

